A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its prostate cancer treatment Talzenna (talazoparib). Members of the Oncologic ...

Former President Joe Biden's prostate cancer diagnosis has sparked an important discussion on screenings. It is a warning for ...

More recently, they’ve discovered some of these same genes can raise a man’s risk for prostate cancer, too. If you carry a gene that could be involved in the development of prostate cancer ...

An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic ...

Researchers have identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an ...

In advanced or metastatic prostate cancer, identifying specific mutations is particularly critical. For instance, mutations in genes such as BRCA1 or BRCA2 ... Get a 320W portable power station and ...

Guidelines created by a multi-disciplinary panel of specialists ... they called out the need for routine genetic testing of patients with advanced prostate cancer and emphatically called out ...

Johnson & Johnson (JNJ) posts Phase 3 trial win for Akkega plus prednisone in metastatic castration-sensitive prostate cancer ...

Standard medical practice is to not test men who have a life expectancy of less than 10 years for prostate cancer.